QL1706 plus chemo after lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer confirmed by biopsy (either squamous or non-squamous type).
- Your cancer is stage II to IIIB and was completely removed with surgery (R0), with recovery enough to start treatment.
- You start the added treatment within 10 weeks (70 days) after surgery.
- Your lung cancer type must be non-squamous if you have that type, and you do not have EGFR “sensitizing” mutations or ALK gene fusions.
- You are well enough for treatment (ECOG performance status 0 or 1) and agree to effective birth control during the study and for 180 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QL2107, against Keytruda, a standard treatment, for people with stage II or IIIA non-small cell lung cancer that has been completely removed by surgery. The goal is to see if QL2107 works as well as Keytruda in preventing the cancer from coming back.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.